RETATRUTIDE

Retatrutide (LY3437943) is Eli Lilly’s breakthrough triple hormone agonist, targeting GLP-1, GIP, and glucagon receptors in a single peptide molecule. Currently in Phase 3 trials (TRIUMPH program), it posts 24–26% weight loss at 48 weeks—eclipsing tirzepatide (21%) and signaling a new frontier in obesity, NASH, and metabolic disease treatment. Unapproved (est. 2026–2027 launch), retatrutide’s glucagon addition torches liver fat and boosts energy expenditure.

This comprehensive review unpacks its science, data, mechanisms, safety, and future—SEO-optimized for “retatrutide weight loss,” “triple agonist peptide,” and “retatrutide vs tirzepatide.”

Development and Molecular Design

Retatrutide builds on tirzepatide’s dual foundation, adding glucagon receptor agonism via optimized peptide engineering:

• Structure: 39-aa with C20 fatty diacid for 6-day half-life.
• Receptor Affinity: GLP-1R (100%), GIPR (100%), GCGR (100%).
• Weekly subQ; potency rivals native hormones.

Born from Lilly’s incretin franchise, it’s positioned to dominate post-semaglutide/tirzepatide markets.

How Retatrutide Works: Triple Threat Mechanism

1. GLP-1: Appetite suppression, gastric slowing, insulin ↑.
2. GIP: Insulin sensitization, adipose remodeling.
3. Glucagon (Unique): ↑Energy expenditure, liver fat oxidation, ketone production—90% steatosis reduction.

Holistic Effect: Brain/gut/liver axis reset; preserves muscle better than duals.

Phase 2 Clinical Data: Unmatched Results

Primary Trial (NEJM 2023, 338 Adults, 48 Weeks)

• NASH: 90%+ resolution at 12mg.
• Muscle: Only 25–30% of loss (vs. 40% duals).

Ongoing Phase 3 (TRIUMPH)

• TRIUMPH-1/2: Obesity (n=2,000+).
• TRIUMPH-3: T2D; TRIUMPH-4: Sleep apnea.

Dosing Protocols (Trial-Based)

• HR Increase: +10–15bpm (glucagon); benign in trials.

Core Benefits: Redefining Metabolic Therapy

1. Obesity: Top-tier loss; 1/3 patients >30%.
2. NASH/MASH: Near-complete reversal.
3. T2D: Beta-cell preservation.
4. CV: Lipids ↑HDL, ↓triglycerides.
5. Apnea/Arthritis: Phase 3 endpoints.
6. Muscle Sparing: Glucagon protects lean mass.

Side Effects and Safety Profile

• Dropout: 7–16% (GI); no MACE signals.
• vs. Tirz: Similar GI, added HR/glucagon sides.

Head-to-Head Comparisons

Current Access and Research Status

• Trials: Recruiting globally (clinicaltrials.gov: NCT05929066).
• UK/EU: Phase 3 sites via NHS.
• Compounded: Gray-market research chem (purity risks).

Pipeline and Future Impact

• Oral Retatrutide: Preclinical.
• Indications: Osteoarthritis, HFpEF, Alzheimer’s.
• Market: $100B obesity space; Lilly frontrunner.

Nature Medicine (2024): “Triple agonists may render bariatrics obsolete.”

Conclusion: Retatrutide’s Triple Threat

With glucagon unlocking metabolic ceilings, retatrutide could end obesity as we know it. Watch TRIUMPH readouts 2025.